|
FDA updated information on recommended AI Sept 4, 2024
|
|
1
|
485
|
September 4, 2024
|
|
QSAR Toolbox - Free software. Any experience?
|
|
18
|
1712
|
September 4, 2024
|
|
Evaluation of the nitrosamine impurities of ACE inhibitors using computational, in vitro, and in vivo methods demonstrate no genotoxic potential -Pub
|
|
7
|
411
|
September 3, 2024
|
|
Pfizer Japan Seeks Partial Change of Champix’s Approval towards Re-Supply
|
|
0
|
143
|
September 2, 2024
|
|
N-Nitroso Metformin Chemistry
|
|
2
|
278
|
September 2, 2024
|
|
N-Nitroso Tizanidine
|
|
1
|
237
|
August 31, 2024
|
|
USP - CPCA Nitrosamines Case Study
|
|
7
|
1454
|
August 30, 2024
|
|
4-(nitroso(vinyl)amino)butanoic acid from Kollidon?
|
|
7
|
296
|
August 29, 2024
|
|
FDA NDSRI limits not aligned with HC/EMA
|
|
0
|
395
|
August 29, 2024
|
|
N-nitroso-rivaroxaban amide
|
|
6
|
1417
|
August 29, 2024
|
|
Anybody inquired about Nitrosamines in Poly bags?
|
|
8
|
1521
|
August 29, 2024
|
|
Resources to help educate reluctant excipient suppliers?
|
|
7
|
328
|
August 28, 2024
|
|
ICH M7 & Nitrosamines Impurities -Updates
|
|
11
|
2813
|
August 28, 2024
|
|
How much Amine and Nitrating agent "Stoichiometric Ratio" required for formation of Nitrosamine impurities?
|
|
3
|
194
|
August 28, 2024
|
|
Define MDD to calculate limit
|
|
45
|
17865
|
August 27, 2024
|
|
Seventh European Medicines Agency - Medicines for Europe annual bilateral meeting
|
|
1
|
101
|
August 27, 2024
|
|
Analytical methodologies to detect N-nitrosamine impurities in active pharmaceutical ingredients, drug products and other matrices -Pub
|
|
0
|
246
|
August 27, 2024
|
|
Health Canada: Nitrosamine impurities Update July 26, 2024
|
|
14
|
1107
|
August 26, 2024
|
|
DMF in API, specification limit in formulation
|
|
5
|
716
|
August 26, 2024
|
|
Synthesis and mutagenic risk of avanafil's potential genotoxic impurities -Pub
|
|
0
|
93
|
August 25, 2024
|
|
Evaluation of the nitrosamine impurities of ACE inhibitors using computational, in vitro, and in vivo methods demonstrate no genotoxic potential-Pub
|
|
0
|
113
|
August 25, 2024
|
|
N-Nitroso Ruxolitinib
|
|
10
|
743
|
August 23, 2024
|
|
Suppressing Nitrosamine Drug Substance Related Impurities by Solid Dispersion
|
|
1
|
269
|
August 22, 2024
|
|
Regulatory Highlights(OPR&D)
|
|
15
|
2193
|
August 21, 2024
|
|
🇧🇷 Guideline for the control of Nitrosamines Rev. 4
|
|
24
|
1477
|
August 21, 2024
|
|
Can we bypass confirmatory testing of DP based on Theoretical Calc. of NDSRI's
|
|
8
|
1174
|
August 20, 2024
|
|
Sitagliptin NTTP nitrosamine impurity maximum active intake level 37ng to 246.7 ng/per day
|
|
29
|
5786
|
August 19, 2024
|
|
NDSRI of Doxepin
|
|
6
|
571
|
August 14, 2024
|
|
📅 FDA - CRCG Updates on Approaches to Acceptable Intakes of Nitrosamine Drug Substance Related Impurities (NDSRIs) and Bioequivalence Assessment for Reformulated Drug Products -Event
|
|
1
|
957
|
August 14, 2024
|
|
AMES Test Study Designs for Nitrosamine Mutagenicity Testing -Pub
|
|
10
|
1196
|
August 13, 2024
|